W

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Business Management
Share
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Source：MarketWatch

Disclaimer：Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.

Related Reading

Live updates: Bitcoin ETFs post a second straight outflow while every other fund turns green

The bitcoin funds shed $120 million on Wednesday, more than double Tuesday's loss. Ether, XRP and solana all took money in. Source：CoinDesk

With the copper price surfing all-time highs, here’s what one CEO thinks about the sector long term

While there’s a bear case to be made on copper if the AI trade blows up, if Trump eschews tariffs or if peace descends over the Persian Gulf, the longterm…

SGX's bitcoin and ether perpetual futures are now open to U.S. institutions

The Singapore Exchange says U.S. institutions can now trade its bitcoin and ether perpetual futures, a milestone that bridges U.S. trading desks with Asian…

Hunter Biden’s LAPTOP blames bots after 98% crash as traders rack up six-figure losses

The team said thin liquidity and automated traders distorted the launch, while Nansen data showed some early buyers sitting on sixfigure losses after the…

Source：https://www.marketwatch.com/story/how-ozempic-maker-novo-nordisk-blew-its-lead-in-glp-1-weight-loss-drugs-can-europe-compete-in-the-high-stakes-global-economy-0a2bcfd0